Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
21 April 2021 | Story Financial Aid

Dear Student

Please take note that the NSFAS appeals process is now open.

FIRST TIME AND NEW APPLICANTS

First time1 and new applicants2 for NSFAS funding for 2021 whose applications were rejected by NSFAS must submit their appeal electronically on the MyNSFAS portal. Financial Aid offices may not accept manual forms for this group of students and may not submit manual appeals for this group to NSFAS. You will be able to track your status on the MyNSFAS portal.

SENIOR RETURNING/CONTINUING STUDENTS

Please see appeal form attached.

The following process is ONLY applicable to NSFAS returning/continuing students and exclude first time
and new applicants for NSFAS funding in 2021.

The following documents must be submitted from your “ufs4life” email address for your appeal to be
considered:
  • 1. Completed and signed appeal form attached herewith.
  • 2. Ensure that the relevant box indicating the reason for your appeal is checked.
  • 3. Signed motivation
  • 4. Supporting documents (e.g. Medical certificates, death certificate etc.) Your appeal can
  • unfortunately not be considered in the absence of documentation in support of your reason and
  • motivation for the appeal.
Please note that NSFAS confirmed that you cannot appeal if you exceeded the N+ period. You can only
submit an appeal for one of the reasons provided on the appeal form.

Please submit the abovementioned required documents as one single combined attachment in legible 
PDF format to your campus specific e-mail address below:
Bloemfontein Campus – NSFASAppealsBfn@ufs.ac.za
Qwaqwa Campus – NSFASAppealsQQ@ufs.ac.za
The closing date for submission of appeals is 30 April 2021 at 16:00 and no appeals will be accepted after
this date.

Issued by

Financial Aid

 

News Archive

UFS Expert: Prof Felicity Burt investigates zoonotic and arboviruses
2017-12-13


 Description: Burt read more 2 Tags: Arboviruses, Felicity Burt, Crimean-Congo haemorrhagic fever, viruses  

Prof Felicity Burt recently received a B-rating from the
National Research
Foundation.
Photo: Sonia Small

Prof Felicity Burt is from the Division of Virology in the Faculty of Health Sciences at the University of the Free State (UFS), as well as the National Health Laboratory Services (NHLS). She currently holds an NRF-DST South African Research Chair in vector-borne and zoonotic diseases.  Professor Burt and her research group investigate arboviruses and zoonotic viruses. 

Prof Burt’s research primarily focuses on host immune responses to arboviral infections specifically characterising humoral and cellular immune responses in patients with infections such as Crimean-Congo haemorrhagic fever (CCHF) virus and Sindbis virus; epitope discovery for development of diagnostic tools; development of molecular and serological assays for surveillance purposes; virus discovery; and the development of vaccines.

Raising awareness of these viruses, defining associated diseases, and developing tools for surveillance programmes will contribute to understanding these pathogens as well as the public health implications.

Leads research group in papilloma viruses
Arboviruses cause outbreaks of disease in South Africa annually. Outbreaks are usually associated with heavy rainfall favouring the breeding of mosquitos, but these viruses also have the capacity to spread and become endemic in new areas where competent vectors are present. 
In addition, she is leading a research group that investigates human papilloma viruses (HPV) associated with head and neck cancers and recurrent laryngeal papilloma.

The focus of this research group is to ascertain the genotypes of HPV causing these diseases, identification of novel biomarkers for early detection, and complete genome sequencing for molecular characterisation of HPV isolates.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept